Foresee Pharmaceuticals benefited from growing demand for its long-acting injection CAMCEVI, a six-month formulation for the treatment of advanced prostate cancer, driving October sales growth. The drug is advancing in multiple clinical indications while continuing to expand its market presence.
In October, CAMCEVI sales in the U.S. end market reached 2,399 units, up approximately 42% from 1,686 units in September, setting a new single-month record. This contributed to revenue of NT$25.15 million for the month, a 296.7% increase month-over-month. From January to October, Foresee Pharmaceuticals’ consolidated revenue totaled about NT$404 million, representing a 2.6% year-on-year increase. October revenue included NT$13.11 million from sales of the six-month CAMCEVI formulation to licensed partners and NT$12.04 million from U.S. end-market revenue sharing of the same formulation.
The six-month CAMCEVI formulation has obtained regulatory approval in the U.S., Canada, Europe, Taiwan, Israel, and the U.K., launching in the U.S. in April 2022 and in Germany in January 2025. The China regulatory submission has entered substantive review. Additionally, the three-month CAMCEVI 21 mg formulation received U.S. approval in August 2025, with a European submission filed to the EMA in March 2025 for review.
On the clinical expansion front, the six-month CAMCEVI is undergoing a multinational, multicenter Phase III trial for its second indication—central precocious puberty (CPP) in children—with key data expected by the end of this year and plans to submit a U.S. regulatory application in the second half of 2026. Another Phase III trial targeting premenopausal breast cancer is ongoing in China.
Beyond prostate cancer, Foresee Pharmaceuticals is actively developing drugs in immunology and respiratory diseases. Its highly selective MMP-12 inhibitor, new chemical entity aderamastat (FP-025), completed a Phase II proof-of-concept trial for allergic asthma in the Netherlands with positive results, and development will extend to rare diseases associated with immune-related fibrosis. Another compound, linvemastat (FP-020), completed a Phase I trial in healthy volunteers in Australia and is planned for severe asthma and chronic obstructive pulmonary disease (COPD).
Additionally, mirivadelgat (FP-045), an oral small-molecule ALDH2 activator for pulmonary hypertension due to interstitial lung disease (PH-ILD), has initiated its Phase II WINDWARD Study in Q2 2025.
Resource: 逸達CAMCEVI銷售創高、多項臨床推進
